Quantcast

Latest Olanzapine Stories

2010-01-04 16:21:16

Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals. In 2003, the Food and Drug Administration (FDA) began requiring a warning on labels of second-generation...

2009-12-14 07:30:00

INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today. ZYPREXA RELPREVV, a long-acting intramuscular injection, sustains the delivery of olanzapine for up to four weeks. Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics...

2009-12-10 05:30:00

NEW YORK, Dec. 10 /PRNewswire-FirstCall/ -- Company remains focused on speeding innovation to patients and delivering greater value to customers. Five strategic business units prepared to maximize growth opportunities in multiple therapeutic areas and geographies. Lilly advances ranking to ninth in worldwide pharmaceutical sales; fastest growing top 10 pharma company in the U.S., major Europe and globally. R&D pipeline boasts more than 60 molecules in clinical development, including...

2009-12-04 15:30:00

INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old. The updated Zyprexa label states that clinicians should take into consideration the increased potential for weight gain and hyperlipidemia in adolescents compared to adults and the...

2009-12-02 07:00:00

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Schizophrenia finds that the...

2009-12-01 13:31:37

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia. In the current issue of Biological Psychiatry, published by Elsevier, researchers discuss this cluster of metabolic side effects and how it may contribute to the risk for diabetes, hypertension, and other medical disorders...

2009-11-05 07:00:00

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that widespread generic erosion of branded atypical antipsychotics will cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to approximately $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Bipolar Disorder finds that the...

69ebba93937a01a1551131e73148d2ae1
2009-10-29 12:41:05

A new study has shown that antipsychotic drugs may be linked to weight gain in kids. Writing in the Journal of the American Medical Association (JAMA), researchers studied the use of name-brand second-generation anti-psychotic drugs, including Abilify, Risperdal, Seroquel and Zyprexa, in 272 kids aged 4 to 19 years. Children involved in the study had not been previously treated with anti-psychotic drugs. "First-time second-generation antipsychotic medication use was associated with...

2009-10-27 16:25:53

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA. Treatment for psychotic disorders, bipolar disorder, and nonpsychotic mental disorders for children and adolescents in the United States often includes second-generation antipsychotic medications....

2009-10-21 05:30:00

INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Higher volume drives revenue growth Stronger dollar results in improved gross margin Earnings per share increase to $.86 (reported) or $1.20 (pro forma non-GAAP) Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (reported) or $4.30 - $4.40 (pro forma non-GAAP) Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2009. $in millions, except per share data Third...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related